Publications by authors named "Sirena K Khanna"
Article Synopsis
- Glioma is the most common brain tumor in adults, and current methods for classifying it rely on molecular changes like IDH1.R132H, which can be risky and may not fully capture the complexity of the tumor.
- A new liquid biopsy test called mt-IDH1 is introduced, allowing for a minimally invasive blood test that detects tumor RNA using just 2 ml of plasma.
- In a study with 133 participants, the mt-IDH1 test showed a sensitivity of 75% and specificity of 88.7%, proving its potential for diagnosis and monitoring of gliomas, with results available in under 4 hours.
Extracellular vesicles (EVs) represent a valuable tool in liquid biopsy with tremendous clinical potential in diagnosis, prognosis, and therapeutic monitoring of gliomas. Compared to tissue biopsy, EV-based liquid biopsy is a low-cost, minimally invasive method that can provide information on tumor dynamics before, during, and after treatment. Tumor-derived EVs circulating in biofluids carry a complex cargo of molecular biomarkers, including DNA, RNA, and proteins, which can be indicative of tumor growth and progression.
View Article and Find Full Text PDFPurpose: Liquid biopsy offers an attractive platform for noninvasive tumor diagnosis, prognostication, and prediction of glioblastoma clinical outcomes. Prior studies report that 30% to 50% of GBM lesions characterized by EGFR amplification also harbor the EGFRvIII mutation.
Experimental Design: A novel digital droplet PCR (ddPCR) assay for high GC content amplicons was developed and optimized for sensitive detection of EGFRvIII in tumor tissue and circulating extracellular vesicle RNA (EV RNA) isolated from the plasma of patients with glioma.